Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226993
Status:
WITHDRAWN
Last Update Posted:
2016-12-01
First Post:
2005-09-13
Brief Title:
Phase III Study of Intratumoral Injection of CPG 7909 a TLR9 Agonist Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Phase III Study of Intratumoral Injection of CPG 7909 A TLR9 Agonist Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides
Status:
WITHDRAWN
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single institution phase I II trial to evaluate the safety and efficacy of intratumoral CpG injections combined with local radiation in patients with mycosis fungoides Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 2 Gy each day CpG injections will be administered into the same tumor site within 24 hours before or 24 hours after each radiation treatment Weekly doses of intratumoral or peritumoral injections CpG will be then administered subcutaneously in the region of previous injections for 23 additional doses The total treatment duration is 24 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCT00226993 | None | None | None |
| 95850 | None | None | None |
| LYMNHL0021 | None | None | None |